Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Datopotamab Deruxtecan Antibody-Drug Conjugate	Jules Bordet Institute	P2	CCC (53)
Datopotamab Deruxtecan Estrogen-Receptor Negative Breast Cancer	Sarah Sammons, MD	P2	CCC (53)
Datopotamab Deruxtecan Estrogen-Receptor Positive Breast Cancer	Sarah Sammons, MD	P2	CCC (53)
Datopotamab Deruxtecan Hormone Receptor Negative Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Datopotamab Deruxtecan Hormone Receptor Positive Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Datopotamab Deruxtecan Metastatic Breast Cancer ( HER2 Negative)	Fudan University	P2	CCC (53)
Datopotamab Deruxtecan Residual Disease	UNC Lineberger Comprehensive Cancer Center	P2	CCC (53)
Datopotamab Deruxtecan Cervical Intraepithelial Neoplasia Grade 2/3	UNC Lineberger Comprehensive Cancer Center	P2	CCC (53)
Datopotamab Deruxtecan Urothelial Carcinoma	AstraZeneca	P2	CCC (53)
DOTA-HUJ-591-GS Castration-Resistant Prostate Carcinoma	Convergent Therapeutics	P2	CCC (53)
ds-8201a Breast Carcinoma	MedSIR	P2	CCC (53)
ds-8201a Hormone Receptor-Positive Breast Cancer	MedSIR	P2	CCC (53)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Collecting Duct Carcinoma	Giuseppe Procopio	P2	CCC (53)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Bladder Adenocarcinoma	Emory University	P2	CCC (53)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Bladder Squamous Cell Carcinoma	Emory University	P2	CCC (53)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Pancreatic Adenocarcinoma	University of Kansas Medical Center	P2	CCC (53)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Kidney Medullary Carcinoma	Giuseppe Procopio	P2	CCC (53)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Bladder Urachal Adenocarcinoma	Emory University	P2	CCC (53)
Gemtuzumab Ozogamicin Acute Myeloid Leukemia, Adult	University of Maryland, Baltimore	P2	CCC (53)
Gemtuzumab Ozogamicin Acute Myeloid Leukemia With Multilineage Dysplasia	National Cancer Institute (NCI)	P2	CCC (53)
Gemtuzumab Ozogamicin Acute Myeloid Leukemia, Inv(16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Acute Megakaryoblastic Leukemia In Adult	National Cancer Institute (NCI)	P2	CCC (53)

Showing 326 to 350 of 1,027 assets

PreviousPage 14 of 42Next